AI assistant
Ascelia Pharma — Share Issue/Capital Change 2021
Mar 31, 2021
3132_rns_2021-03-31_e6800761-22cf-48fc-b792-2a9ac39afa3b.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
PRESS RELEASE
31 March 2021 14:00:00 CEST
ASCELIA PHARMA
Number of shares and votes in Ascelia Pharma AB
During March 2021, the number of shares and votes in Ascelia Pharma AB have increased by 481,573 due to the exercise of in total 481,573 warrants under the company's incentive program.
Per 31 March 2021, the number of shares amounts 29,178,807, whereof 28,668,262 are ordinary shares with one vote per share and 510,545 are class C shares with one-tenth of a vote per share. The total number of votes in the company amounts to 28,719,316.5.
About Us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.
About Mangoral
Mangoral (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Mangoral, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.
About Oncoral
Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development.
This information is information that Ascelia Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2021-03-31 14:00 CEST.
Ascelia Pharma • Hyllie Boulevard 34 • SE-215 32 Malmö
Attachments
Number of shares and votes in Ascelia Pharma AB
Ascelia Pharma • Hyllie Boulevard 34 • SE-215 32 Malmö